Diabetic retinopathy in sub-Saharan Africa: Meeting the challenges of an emerging epidemic

BMC Medicine

Volumn 11, Issue 1, 2013, Pages

  Burgess, Philip I ^a   Msukwa, Gerald ^b   Beare, Nicholas A V ^c,d  

^a UNIVERSITY OF MALAWI   (Malawi)

^b QUEEN ELIZABETH CENTRAL HOSPITAL   (Malawi)

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Africa; Diabetic retinopathy; Epidemiology; Health services; Screening

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN ANTIBODY;

ARTICLE; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DIABETIC RETINOPATHY; EMPOWERMENT; EPIDEMIC; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HEALTH SERVICE; HUMAN; INTEGRATED HEALTH CARE SYSTEM; LASER COAGULATION; LOW LEVEL LASER THERAPY; MEDICAL RESEARCH; POLITICAL SYSTEM; POVERTY; PRIMARY PREVENTION; RETINA MACULA EDEMA; RETINA MACULOPATHY; SCREENING; SLIT LAMP; SOCIAL ENVIRONMENT; SOCIETY; VISUAL IMPAIRMENT;

AFRICA SOUTH OF THE SAHARA; DELIVERY OF HEALTH CARE; DIABETIC RETINOPATHY; EPIDEMICS; HUMANS; RISK FACTORS;

EID: 84879800827     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-11-157     Document Type: Article

References (58)

1. Gill G, Mbanya JC, Ramaiya K, Tesfaye S. A sub-Saharan African perspective of diabetes. Diabetologia 2009, 52:8-16. 10.1007/s00125-008-1167-9, 18846363.
2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010, 87:4-14. 10.1016/j.diabres.2009.10.007, 19896746.
3. Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. BJO 2012, 96:614-618.
4. Marshall G, Garg SK, Jackson WE, Holmes DL, Chase HP. Factors influencing the onset and progression of diabetic retinopathy in subjects with insulin-dependent diabetes mellitus. Ophthalmology 1993, 100:1133-1139.
5. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986. The Diabetes Control and Complications Trial Research Group.
6. Davis MD, Fisher MR, Gangnon RE, Barton F, Aiello LM, Chew EY, Ferris FL, Knatterud GL. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Invest Ophthalmol Vis Sci 1998, 39:233-252.
7. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, Matthews DR. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 2001, 44:156-163. 10.1007/s001250051594, 11270671.
8. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703-713. 10.1136/bmj.317.7160.703, 28659, 9732337, UK Prospective Diabetes Study Group.
9. Agardh CD, Agardh E, Torffvit O. The association between retinopathy, nephropathy, cardiovascular disease and long-term metabolic control in type 1 diabetes mellitus: a 5 year follow-up study of 442 adult patients in routine care. Diabetes Res Clin Pract 1997, 35:113-121. 10.1016/S0168-8227(97)01386-7, 9179466.
10. Gallego PH, Craig ME, Hing S, Donaghue KC. Role of blood pressure in development of early retinopathy in adolescents with type 1 diabetes: prospective cohort study. BMJ 2008, 337:a918. 10.1136/bmj.a918, 2526183, 18728082.
11. Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, Rogulja-Pepeonik Z, Fuller JH. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998, 351:28-31. 10.1016/S0140-6736(97)06209-0, 9433426.
12. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M, FIELD study investigators Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861. FIELD study investigators.
13. The Diabetic Retinopathy Study Research Group Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. Ophthalmology 1981, 88:583-600. The Diabetic Retinopathy Study Research Group.
14. Early Treatment Diabetic Retinopathy Study research group Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthal 1985, 103:1796-1806. Early Treatment Diabetic Retinopathy Study research group.
15. Burgess PI, Maccormick IJ, Harding SP, Bastawrous A, Beare NA, Garner P. Epidemiology of diabetic retinopathy and maculopathy in Africa: a systematic review. Diabet Med 2013, 30:399-412. 10.1111/j.1464-5491.2012.03756.x, 22817387.
16. Cockburn N, Steven D, Lecuona K, Joubert F, Rogers G, Cook C, Polack S. Prevalence, causes and socio-economic determinants of vision loss in Cape Town, South Africa. PLoS One 2012, 7:e30718. 10.1371/journal.pone.0030718, 3282720, 22363476.
17. World Health Organization Coding Instructions for the WHO/PBL Eye Examination Record (version III). PBL/88.1 1988, Geneva: WHO, World Health Organization.
18. Younis N, Broadbent DM, Harding SP, Vora JP. Prevalence of diabetic eye disease in patients entering a systematic primary care-based eye screening programme. Diabet Med 2002, 19:1014-1021.
19. Younis N, Broadbent D, Vora J, Harding S. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet 2003, 361:195-200. 10.1016/S0140-6736(03)12267-2, 12547541.
20. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984, 102:527-532. 10.1001/archopht.1984.01040030405011, 6367725.
21. Tapp RJ. Six year incidence and progression of diabetic retinopathy: results from the Mauritius diabetes complication study. Diabetes Res Clin Pract 2006, 73:298-303. 10.1016/j.diabres.2006.02.009, 16584802.
22. Gill GV. Long-term (20 years) outcome and mortality of Type 1 diabetic patients in Soweto, South Africa. Diabet Med 2005, 22:1642-6. 10.1111/j.1464-5491.2005.01712.x, 16401306.
23. Stevenson CR, Forouhi NG, Roglic G, Williams BG, Lauer JA, Dye C, Unwin N. Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidence. BMC Publ Health 2007, 7:234.
24. Young FCJ, Johnstone LK, Unwin NC. A review of co-morbidity between infectious and chronic disease in Sub Saharan Africa: TB and diabetes mellitus. HIV and metabolic syndrome. Global Health 2009, 5:9. 10.1186/1744-8603-5-9, 2753337, 19751503.
25. Mash B, Powell D, du Plessis F, van Vuuren U, Michalowska M, Levitt N. Screening for diabetic retinopathy in primary care with a mobile fundal camera-evaluation of a South African pilot project. S Afr Med J 2007, 97:1284-8.
26. Joannou J, Kalk WJ, Mahomed I, Ntsepo S, Berzin M, Joffe BI, Raal FJ, Sachs E, van der Merwe MT, Wing JR. Screening for diabetic retinopathy in South Africa with 60 degrees retinal colour photography. J Intern Med 1996, 239:43-47. 10.1046/j.1365-2796.1996.413755000.x, 8551199.
27. Read O, Cook C. Retinopathy in diabetic patients evaluated at a primary care clinic in Cape Town. S Afr Med J 2007, 97:941-942. 4.
28. Carmichael TR, Carp GI, Welsh ND, Kalk WJ. Effective and accurate screening for diabetic retinopathy using a 60 degree mydriatic fundus camera. S Afr Med J 2005, 95:57-61.
29. Mumba M, Hall A, Lewallen S. Compliance with eye screening examinations among diabetic patients at a Tanzanian referral hospital. Ophthalmic Epidemiol 2007, 14:306-310. 10.1080/09286580701272079, 17994440.
30. Kirigia JM, Sambo HB, Sambo LG, Barry SP. Economic burden of diabetes mellitus in the WHO African region. BMC Int Health Hum Rights 2009, 9:6. 10.1186/1472-698X-9-6, 2674592, 19335903.
31. Bradshaw D, Norman R, Pieterse D, Levitt NS, South African Comparative Risk Assessment Collaborating Group Estimating the burden of disease attributable to diabetes in South Africa in 2000. S Afr Med J 2007, 97:700-706. South African Comparative Risk Assessment Collaborating Group.
32. Fong DS, Aiello L, Gardner TW, American Diabetes Association Retinopathy in diabetes. Diabetes Care 2004, 27:S84-S87. 10.2337/diacare.27.2007.S84, 14693935, American Diabetes Association.
33. Zhang PZX, Brown JB, Vistisen D, Sicree RA, Shaw J, Nichols GA. Economic Impact of Diabetes. Diabetes Atlas, IDF 2009, International Diabetes Federation: Brussels, 4.
34. WHO Country cooperation strategy Malawi. [http://www.who.int/countryfocus/cooperation_strategy/ccsbrief_mwi_en.pdf].
35. Report on the United Nations high level meeting on non-communicable disease prevention and control. [http://www.who.int/nmh/events/un_ncd_summit2011/en/].
36. Resnikoff S, Felch W, Gauthier TM, Spivey B. The number of ophthalmologists in practice and training worldwide: a growing gap despite more than 200,000 practitioners. Br J Ophthalmol 2012, 96:783-787. 10.1136/bjophthalmol-2011-301378, 22452836.
37. Bastawrous A, Hennig BD. The global inverse care law: a distorted map of blindness. Br J Ophthalmol 2012, 96:1357-1358. 3457914, 22740107.
38. UN data Country profile Malawi 2009. [http://data.un.org/CountryProfile.aspx?crName=MALAWI], UN data.
39. WHO World Health Report 2002: Reducing risks, promoting healthy life Geneva: WHO, [http://www.who.int/whr/2002/].
40. Whiting DR, Hayes L, Unwin NC. Diabetes in Africa. Challenges to health care for diabetes in Africa. J Cardiovasc Risk 2003, 10:103-110. 10.1097/00043798-200304000-00005, 12668907.
41. Mayosi BM, Flisher AJ, Lalloo UG, Sitas F, Tollman SM, Bradshaw D. The burden of non-communicable diseases in South Africa. Lancet 2009, 374:934-47. 10.1016/S0140-6736(09)61087-4, 19709736.
42. Floyd S, Molesworth A, Dube A, et al. Population-level reduction in adult mortality after extension of freeanti-retroviral therapy provision into rural areas in northern Malawi. PLoS One 2010, 5:e13499. 10.1371/journal.pone.0013499, 2957442, 20976068.
43. Nguyen C, Cheng-Lai A. The polypill: a potential global solution to cardiovascular disease. Cardiol Rev 2013, 21:49-54. 10.1097/CRD.0b013e3182755429, 23018668.
44. Network DRCR. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010, 117:1064-1077. 10.1016/j.ophtha.2010.02.031, 2937272, 20427088.
45. Virgili G, Parravano M, Menchini F, Brunetti M. Cochrane Intervention review: Anti-angiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. The Cochrane library [http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007419.pub3/abstract].
46. Rajendram R, Fraser-Bell S, Kaines A, Michaelides M, Hamilton RD, Esposti SD, Peto T, Egan C, Bunce C, Leslie RD, Hykin PG. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 2012, 130:972-979. 10.1001/archophthalmol.2012.393, 22491395.
47. Harding SP, Broadbent DM, Neoh C, White MC, Vora J. Sensitivity and specificity ofphotography and direct ophthalmoscopy in screening for sight threatening eye disease: the Liverpool diabetic eye study. BMJ 1995, 311:1131-1135. 10.1136/bmj.311.7013.1131, 2551056, 7580708.
48. Jones S, Edwards RT. Diabetic retinopathy screening: a systematic review of the economic evidence. Diabet Med 2010, 27:249-256.
49. NHS Diabetic eye screening programme. [http://diabeticeye.screening.nhs.uk].
50. Younis N, Broadbent DM, Vora JP, Harding SP. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet 2003, 361:195-200. 10.1016/S0140-6736(03)12267-2, 12547541.
51. Henricsson M, Nilsson A, Groop L, Heijl A, Janzon L. Prevalence of diabetic retinopathy in relation to age at onset of the diabetes, treatment, duration and glycaemic control. Acta Ophthalmol Scand 1996, 74:523-527.
52. Kristinsson JK, Stefonsson E, Janasson F, Goslason I, Bjornsson S. Screening for eye disease in type 2 diabetes mellitus. Acta Ophthalmol 1994, 72:341-346.
53. Zhang X, Saaddine JB, Chou CF, Cotch MF, Cheng YJ, Geiss LS, Gregg EW, Albright AL, Klein BE, Klein R. Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA 2010, 304:649-656. 10.1001/jama.2010.1111, 2945293, 20699456.
54. The ACCORD Study Group and ACCORD Eye Study Group Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010, 363:233-244. The ACCORD Study Group and ACCORD Eye Study Group.
55. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412. 10.1136/bmj.321.7258.405, 27454, 10938048.
56. James M, Turner D, Broadbent DM, Vora J, Harding SP. Cost effectiveness analysis of screening for sight threatening diabetic eye disease. BMJ 2000, 320:1627-1631. 10.1136/bmj.320.7250.1627, 27406, 10856062.
57. Murthy KR, Murthy PR, Kapur A, Owens DR. Mobile diabetes eye care: experience in developing countries. Diabetes Res Clin Pract 2012, 97:343-349. 10.1016/j.diabres.2012.04.025, 22613266.
58. Rachapelle S, Legood R, Alavi Y, Lindfield R, Sharma T, Kuper H, Polack S. The cost-utility of telemedicine to screen for diabetic retinopathy in India. Ophthalmology 2013, 120:566-573. 10.1016/j.ophtha.2012.09.002, 23211635.